Top

Breast Cancer Research and Treatment

Published in:

01-12-2018 | Brief Report

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer

Authors: Javier Pérez-Peña, Balázs Győrffy, Eitan Amir, Atanasio Pandiella, Alberto Ocaña

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Abstract

Introduction

FOXM1 is a transcription factor that has been implicated in the genesis of several tumors by regulating the expression of genes involved in the mitotic process.

Methods

Transcriptomic enrichment analysis was performed to evaluate deregulated pathways in breast cancer, and relapse-free survival associated with the upregulated genes of FOXM1 signature was explored using the KM Plotter online tool. Treatment with bromodomain and extraterminal (BET) inhibitor JQ1 was explored in breast cancer cell lines to evaluate FOXM1 by qPCR and proliferation by MTT colorimetric assays.

Results

The FOXM1 gene signature was clearly deregulated in breast cancer patients, particularly in the basal-like subgroup where it was linked with detrimental prognosis. Treatment with the BET inhibitor JQ1 reduced the expression of FOXM1, decreasing cell proliferation in a panel of cell lines, being more active in the basal-like subtype, MDA-MB-231 and HS-578T. Knockdown of FOXM1 or treatment with JQ1 reduced genes included in the FOXM1 signature. Similarly, genes downregulated by the FOXM1 small interfering RNA approach were associated with detrimental outcome in breast cancer patients. Finally, we observed that FOXM1 was amplified in the triple-negative breast cancer subtype in around 15% of patients.

Conclusion

Our study demonstrates that activation of the FOXM1 pathway has a prognostic role in breast cancer. JQ1 can modulate the expression of the FOXM1-gene interacting network, opening the opportunity for the evaluation of this compound in breast cancer patients.

Available only for authorised users

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339(6127):1546–1558CrossRef

Ocana A, Pandiella A (2010) Personalized therapies in the cancer “omics” era. Mol Cancer 9:202CrossRef

Ocana A, Pandiella A, Siu LL, Tannock IF (2010) Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol 8:200–209CrossRef

Ocana A, Serrano R, Calero R, Pandiella A (2009) Novel tyrosine kinase inhibitors in the treatment of cancer. Curr Drug Targets 10(6):575–576CrossRef

Ocana A, Nieto-Jimenez C, Pandiella A (2017) BET inhibitors as novel therapeutic agents in breast cancer. OncoTarget 8(41):71285–71291CrossRef

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I et al (2010) Selective inhibition of BET bromodomains. Nature 468(7327):1067–1073CrossRef

Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H et al (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15(1):67–78CrossRef

Perez-Pena J, Serrano-Heras G, Montero JC, Corrales-Sanchez V, Pandiella A, Ocana A (2016) In silico analysis guides selection of BET inhibitors for triple-negative breast cancer treatment. Mol Cancer Ther 15(8):1823–1833CrossRef

Ocana A, Pandiella A (2017) Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. OncoTarget 8(13):22218–22234CrossRef

10.

Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J et al (2016) Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529(7586):413–417CrossRef

11.

Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E et al (2010) Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 42(5):454–458CrossRef

12.

Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O’Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J et al (2013) Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis 34(10):2300–2308CrossRef

13.

Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W (2011) Identification of early molecular markers for breast cancer. Mol Cancer 10(1):15CrossRef

14.

Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A et al (2013) TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS ONE 8(5):e63712CrossRef

15.

Maire V, Nemati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G et al (2013) Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res 73(2):813–823CrossRef

16.

Maubant S, Tesson B, Maire V, Ye M, Rigaill G, Gentien D, Cruzalegui F, Tucker GC, Roman-Roman S, Dubois T (2015) Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells. PLoS ONE 10(4):e0122333CrossRef

17.

Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle JC, Stamenkovic I (2011) Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS ONE 6(5):e18640CrossRef

18.

Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9(2):121–132CrossRef

19.

Gyorffy B, Surowiak P, Budczies J, Lanczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE 8(12):e82241CrossRef

20.

Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123(3):725–731CrossRef

21.

Pongor L, Kormos M, Hatzis C, Pusztai L, Szabo A, Gyorffy B (2015) A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients. Genome Med 7:104CrossRef

22.

Bergamaschi A, Madak-Erdogan Z, Kim YJ, Choi YL, Lu H, Katzenellenbogen BS (2014) The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res 16(5):436CrossRef

23.

Lin X, Huang X, Uziel T, Hessler P, Albert DH, Roberts-Rapp LA, McDaniel KF, Kati WM, Shen Y (2017) HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues. Mol Cancer Ther 16(2):388–396CrossRef

24.

Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH (2005) FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7(2):126–136CrossRef

25.

Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, Major ML, Gusarova GA, Yoder HM, Costa RH et al (2006) The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 66(4):2153–2161CrossRef

26.

Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, Tan Y, Ackerson T, Costa RH (2005) Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25(24):10875–10894CrossRef

27.

Hamurcu Z, Ashour A, Kahraman N, Ozpolat B (2016) FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. OncoTarget 7(13):16619–16635CrossRef

Title: Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer
Authors: Javier Pérez-Peña
Balázs Győrffy
Eitan Amir
Atanasio Pandiella
Alberto Ocaña
Publication date: 01-12-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4965-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer

A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer

Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells

Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy

Labour productivity loss caused by premature deaths associated with breast cancer: results from Spain over a 10-year period

The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view

Keynote webinar | Spotlight on antibody–drug conjugates in cancer